• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore, Oct. 16 The market meltdown has put paid to one more listing plan for now: that of Biocon’s custom research subsidiary, Syngene International.

“We will not list Syngene this fiscal. It would be suicidal,” Biocon’s CMD, Ms Kiran Mazumdar-Shaw, emphatically told a news conference on Thursday. Biocon had planned to tap the capital market for Syngene during this fiscal.

Syngene’s numbers, she said, caused concern last quarter but it has now bounced back with 21 per cent growth over the last quarter and nine per cent year on year. The company has a cash reserve of Rs 355 crore from the sale of its enzymes business last year.

More Stories on : IPOs | Research & Development | Bio-tech & Genetics

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line